Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS

Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54

Published:2016-06 Issue:23 Volume:67 Page:2732-2740
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Bhatt Deepak L.,Bonaca Marc P.,Bansilal Sameer,Angiolillo Dominick J.,Cohen Marc,Storey Robert F.,Im Kyungah,Murphy Sabina A.,Held Peter,Braunwald Eugene,Sabatine Marc S.,Steg Ph. Gabriel

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry;Cavender;Circulation,2015

2. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis;Bhatt;JAMA,2010

3. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus;Bhatt;Am J Cardiol,2002

4. Abciximab reduces mortality in diabetics following percutaneous coronary intervention;Bhatt;J Am Coll Cardiol,2000

5. Antiplatelet therapy following myocardial infarction in patients with diabetes;Bhatt;JAMA,2012

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithrombotic Therapy in Patients with Chronic Coronary Syndromes;Interventional Cardiology Clinics;2024-10

2. 2024 ESC Guidelines for the management of chronic coronary syndromes;European Heart Journal;2024-08-30

3. Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?;Current Cardiology Reports;2024-04-18

4. Long-term clinical outcomes in elderly patients with chronic total occlusion and type 2 diabetes: the impact of coronary collateralization following successful recanalization;Cardiology Plus;2024-04

5. Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy;European Heart Journal - Cardiovascular Pharmacotherapy;2024-03-07